Related by context. All words. (Click for frequent words.) 72 ISIS # 70 PSN# [002] 70 CCX# 70 PEG PAL 70 ganetespib 70 rNAPc2 70 selective androgen receptor modulator 70 favorable pharmacokinetic profile 70 Triolex 69 INCB# [001] 69 AzaSite Plus 69 elotuzumab 69 Xanafide 69 CORT # 69 INCB# [002] 69 PRTX 69 JAK inhibitor 69 tanespimycin 69 CRx 68 PRT# 68 PEG SN# 68 Synavive 68 PDE4 inhibitor 68 ENMD # 68 Panzem R 68 APOPTONE 68 AEGR 68 HGS ETR1 68 lomitapide 68 RDEA# 68 Tezampanel 68 Darusentan 68 MAP# 68 BAY #-# 68 CA4P 68 Phenoptin 68 OXi# 68 ELND# 67 PXD# 67 oral prodrug 67 Azedra 67 fosbretabulin 67 sodium glucose cotransporter 67 ruxolitinib 67 orally administered inhibitor 67 Sym# 67 Phase Ib study 67 EOquin 67 CTAP# Capsules 67 JAK1 67 R#/MEM # 67 Perifosine 67 GFT# 67 neratinib 67 celgosivir 67 TELINTRA 67 virus HCV protease inhibitor 67 Phase 2a trial 67 LAF# 67 metaglidasen 67 RLY# 67 HspE7 67 TBC# 67 AEG# 67 DCCR 67 PRX # 67 Bicifadine 67 XmAb# 67 phase IIb clinical 67 PEG Interferon lambda 66 TPI ASM8 66 TELCYTA 66 Varespladib 66 liposomal formulation 66 ularitide 66 phase IIa clinical 66 ALN PCS 66 CIMZIA TM 66 Mipomersen 66 pradefovir 66 Zerenex 66 Ambrisentan 66 RGB # 66 HCV protease inhibitor 66 IAP inhibitor 66 Tyrima 66 preclinical efficacy 66 Panzem R NCD 66 thymalfasin 66 brivaracetam 66 Traficet EN 66 Chemophase 66 BCX# 66 MAGE A3 ASCI 66 PLK1 SNALP 66 alvespimycin 66 Pimavanserin 66 pan HDAC inhibitor 66 SRT# [003] 66 CIMZIA ™ 66 alvimopan 66 GSK# [001] 66 PF # [001] 66 telaprevir VX 66 YONDELIS 66 diabetic neuropathic pain 66 pharmacodynamic properties 66 nonclinical studies 66 DAVANAT 65 MYDICAR ® 65 pharmacokinetic PK profile 65 TLK# 65 bafetinib 65 ATL# [001] 65 BAL# [002] 65 ALN TTR# 65 GALNS 65 Ostarine 65 TRIOLEX 65 AEZS 65 mapatumumab 65 TG# [003] 65 eprotirome 65 elesclomol 65 obatoclax 65 histone deacetylase HDAC inhibitor 65 NGX# 65 forodesine 65 ALN VSP 65 INT# [002] 65 urocortin 2 65 MGCD# [001] 65 valopicitabine 65 RG# [001] 65 bremelanotide 65 Archexin 65 PDX pralatrexate 65 IRX 2 65 pertuzumab 65 Carfilzomib 65 atacicept 65 Vilazodone 65 Phase IIa trial 65 TRO# 65 Androxal TM 65 HuMax EGFr 65 Phase 1b clinical trials 65 TMC# [002] 65 Amigal 65 PMX # 65 DDP# 65 6R BH4 65 Amrubicin 65 XL# XL# XL# 65 MEK inhibitor 65 CoFactor 65 Bezielle 65 orally bioavailable 65 TriRima 65 LE SN# 65 iSONEP 65 riociguat 64 Hsp# inhibitor 64 hematological cancers 64 oral ridaforolimus 64 investigational humanized monoclonal antibody 64 ICA # 64 OncoVEX GM CSF 64 teduglutide 64 enzastaurin 64 CR# vcMMAE 64 Phase 2b study 64 Phase 2a clinical 64 Apoptone 64 adecatumumab 64 Glufosfamide 64 Dapagliflozin 64 Symadex 64 CUDC 64 Phase Ib clinical trials 64 ACAPODENE 64 pharmacokinetic PK study 64 GLP toxicology studies 64 Phase Ib clinical 64 GSK# [002] 64 HGS ETR2 64 ELACYT 64 dacetuzumab 64 S/GSK# 64 preclinically 64 otelixizumab 64 HQK 64 CBLC# 64 Azedra TM 64 novel VDA molecule 64 pharmacokinetic PK 64 torezolid phosphate 64 Phase 2a 64 Guanilib 64 eltrombopag 64 RSD# 64 apremilast 64 UPLYSO 64 velafermin 64 ALN HPN 64 NXL# 64 huC# DM4 64 custirsen 64 SCH # 64 evaluating tivozanib 64 DB# [003] 64 nitazoxanide 64 anti amnesic 64 Phase 2b 64 CEQ# 64 pharmacodynamic 64 Phase 1b 64 pharmacodynamic effects 64 CCR9 antagonist 64 AQ4N 64 rHuPH# 64 Sudhir Agrawal D.Phil 64 Golimumab 64 lesinurad 64 secretory phospholipase A2 sPLA2 64 Zybrestat 64 bosutinib 64 Bortezomib 64 tezampanel 64 preclinical studies 64 Phase 1b trial 64 Azixa 64 refractory gout 64 Panzem 64 Tekamlo 64 registrational trial 64 ApoB SNALP 64 INCB# [003] 64 Imprime PGG 64 CANCIDAS 64 AZD# 64 tipifarnib 64 Exelixis compounds 64 Phase 1b clinical 63 squalamine 63 Ophena TM 63 QNEXA 63 Solazed TM 63 posaconazole 63 MGd 63 PNP inhibitor 63 #ME# 63 dirucotide 63 MDV# 63 Asentar 63 Aurexis 63 Targretin 63 polymerase inhibitor 63 HuLuc# 63 CYT# 63 LY# [003] 63 Plicera 63 Troxatyl 63 LymphoStat B 63 GAMMAGARD 63 PHX# 63 Phase Ib 63 ALN TTR 63 Factor VIIa 63 EDEMA3 trial 63 Squalamine 63 mertansine 63 ALTU 63 Fibrillex TM 63 teriflunomide 63 ocular formulation 63 Phase #b/#a trial 63 LY# [002] 63 Genasense ® oblimersen 63 Posiphen 63 mipomersen 63 alagebrium 63 INC# 63 proteasome inhibitor 63 HGS# 63 VitiGam 63 Avanafil 63 Debio 63 investigational compound 63 Marqibo 63 cariprazine 63 SPP# [001] 63 eniluracil 63 Aflibercept 63 Gabapentin GR 63 talactoferrin 63 galiximab 63 Alocrest 63 ongoing Phase 1b 63 GRN#L 63 nalbuphine ER 63 crizotinib PF # 63 SYN# 63 viral kinetics 63 SinuNase TM 63 Epanova 63 brostallicin 63 Phase 1a clinical 63 HCV protease 63 cannabinor 63 Serdaxin 63 bicifadine 63 reslizumab 63 PROMACTA 63 LibiGel ® 63 ATL/TV# 63 Amplimexon 63 protein kinase inhibitor 63 PSMA ADC 63 AzaSite Xtra 63 angiotensin receptor blocker ARB 63 varespladib 63 Stedivaze 63 Rasilez Tekturna 63 pomalidomide 63 sorafenib tablets 63 Dacogen injection 63 HuMax CD4 63 solithromycin 63 Azedra ™ 63 Pharmacokinetic PK 63 Aliskiren 63 Cleviprex TM clevidipine 63 adenosine injection 63 IMA# 63 tubulin inhibitor 63 triphendiol 63 JAK inhibitors 63 axitinib 63 Phase IIb trials 63 DPP4 63 Capesaris 63 RhuDex ® 63 Pradefovir 63 Phase IIa clinical trials 63 Dasatinib 63 methylnaltrexone 63 selective modulator 63 iroxanadine 63 Cloretazine R VNP#M 63 Corlux 63 Alinia 63 IFN α 62 MEK inhibitors 62 #D#C# 62 TKM ApoB 62 targeted radiotherapeutic 62 lumiliximab 62 CORLUX CORT # 62 Onalta 62 somatostatin analogue 62 XL# anticancer compounds 62 sorafenib Nexavar 62 FOLOTYN ® 62 PCK# 62 Locteron 62 LEP ETU 62 HuMax CD# 62 tasimelteon 62 Phase 2b trial 62 phase Ib 62 Omacetaxine 62 trastuzumab emtansine T DM1 62 mGluR5 negative 62 Epratuzumab 62 vascular disrupting agent 62 docetaxel Taxotere R 62 CaPre TM 62 OMNARIS HFA 62 multi kinase inhibitor 62 BZL# 62 phase IIb trial 62 QVA# 62 Virulizin ® 62 TACI Ig 62 BENICAR HCT 62 Spiegelmer ® 62 CXB# 62 TREANDA 62 Icatibant 62 deforolimus 62 vidofludimus 62 Oral NKTR 62 oral FTY# 62 Excellarate 62 OvaRex ® MAb 62 glufosfamide 62 orBec 62 anidulafungin 62 TOCOSOL Paclitaxel 62 Xcytrin R 62 pharmacokinetics PK 62 VQD 62 GLYX 62 cMET 62 Locteron ® 62 ZYBRESTAT 62 diarrhea predominant irritable 62 pralatrexate 62 phase IIb study 62 plasma kallikrein inhibitor 62 Sapacitabine 62 T Pred 62 AAG geldanamycin analog 62 pharmacokinetic parameters 62 Phase 2b clinical 62 atrasentan 62 danoprevir 62 VAPRISOL 62 MB# [004] 62 omecamtiv mecarbil 62 Hsp# inhibitors 62 EndoTAG TM -1 62 KRN# 62 ostarine 62 cytoprotective 62 Reverset 62 ponatinib 62 SARMs 62 velafermin belinostat 62 hematological malignancies 62 darusentan 62 SinuNase ™ 62 HSP# inhibitor 62 CD# antibody [001] 62 Phase IIa clinical 62 CD# monoclonal antibody 62 SAR# [004] 62 dose cohort 62 Allovectin 7 R 62 Onconase 62 PrevOnco 62 CINQUIL 62 XL# XL# XL# XL# 62 elvitegravir 62 LymphoStat B TM 62 safety tolerability pharmacokinetic 62 Romidepsin 62 ALKS 62 Naproxcinod 62 CORLUX 62 ISENTRESS 62 Aclidinium 62 Ocrelizumab 62 phase 2a 62 Trofex 62 Safinamide 62 IPL# 62 Phase IIa trials 62 Phase 2b clinical trials 62 SILENOR 62 Muraglitazar 62 Valortim 62 oral rivaroxaban 62 dasatinib Sprycel ® 62 sapacitabine 62 dextromethorphan quinidine 62 Sphingomab 62 bevacizumab Avastin ® 62 CK # 62 ELND-#/AZD-# 62 CDK inhibitor 62 aflibercept 62 Meets Primary Endpoint 62 sargramostim 62 Phase #/#a trial 62 Rigel R# 62 ADVANCE PD 62 potent antiviral 62 Androxal ® 62 XP# XP# 62 Tarceva TM 62 administered subcutaneously 62 BioVant 62 Randomized Phase 62 bazedoxifene 62 pivotal Phase III 62 GRN# 62 HCD# [002] 62 voreloxin 62 NLX P# 62 Zoraxel 62 intranasal formulation 62 APD# 62 compound INCB# 62 APTIVUS 62 LymphoStat B belimumab 62 dose escalation Phase 62 Radezolid 62 Anturol 62 Shigamabs ® 62 LEVADEX 62 MYDICAR 62 Ticagrelor 62 Phase #b/#a clinical 62 Ozarelix 62 VIAtab TM 61 CINOD 61 BrachySil 61 ProSavin 61 QLT# 61 Aplidin 61 Interferon beta 1a 61 KNS # 61 investigational monoclonal antibody 61 zileuton 61 Omacetaxine mepesuccinate 61 generation antisense inhibitor 61 lintuzumab 61 depsipeptide 61 MEK inhibitor RDEA# 61 Phase IIb clinical 61 VA# [002] 61 GED aPC 61 radiation sensitizer 61 torsemide ER 61 THR beta agonist 61 lexidronam injection 61 SGLT2 61 Iluvien ® 61 ATACAND 61 nilotinib 61 mTOR inhibitor 61 favorable tolerability 61 AIR# [001] 61 DXL# 61 endothelin receptor antagonists 61 CRMD# 61 NV1FGF 61 EOquin TM 61 oral picoplatin 61 AP# [003] 61 GAMMAGARD LIQUID 61 NKTR 61 trastuzumab Herceptin R 61 FOLFOX6 chemotherapy regimen 61 anticancer compound 61 octreotide acetate 61 MEK Inhibitor 61 maximally tolerated dose 61 TRV# [001] 61 INVIRASE 61 highly selective inhibitor 61 Cloretazine 61 compound ITMN 61 Tekturna HCT 61 ACTEMRA TM 61 ARRY 61 Cannabinor 61 multicenter Phase II 61 erlotinib Tarceva ® 61 tolerability profiles 61 davunetide intranasal AL 61 Alzhemed TM 61 Multimeric 61 Viramidine 61 fenofibric acid 61 inhibitor RG# 61 elacytarabine 61 belinostat 61 PEP# [003] 61 Atiprimod 61 EP #R 61 NVA# 61 trastuzumab DM1 T DM1 61 Micardis ® 61 HER2 positive metastatic breast 61 C1 INH 61 phase IIb 61 sunitinib malate 61 NeuroSTAT ® 61 BiTE antibody 61 radezolid 61 EDEMA4 61 Iloperidone 61 LT NS# 61 Genz # 61 partial agonist 61 AeroLEF TM 61 SAR# [002] 61 tramiprosate Alzhemed TM 61 vascular disrupting agents 61 CLORETAZINE TM VNP#M 61 potent inhibitor 61 Actilon 61 lucinactant 61 severe hypercholesterolemia 61 ILUVIEN ® 61 TLR7 61 cobiprostone 61 Firazyr 61 A3 adenosine receptor 61 Thiarabine 61 Rasilez 61 pharmacodynamic PD 61 midstage clinical 61 omega interferon 61 Androxal 61 BRAF inhibitor 61 neuroprotective properties 61 pharmacokinetic profile 61 Telintra 61 mGluR5 NAM 61 placebo controlled Phase 61 BRIM2 61 Phase Ia 61 AMD# [003] 61 HoFH 61 Aurora kinase 61 GRNCM1 61 maribavir 61 Pegasys ® 61 Panitumumab 61 regadenoson 61 Pivotal Phase III 61 Panzem NCD 61 Rezular 61 ADAGIO study 61 Relivar 61 FM VP4 61 adipiplon 61 TH# [003] 61 myelofibrosis polycythemia vera 61 telbivudine 61 Hsp# Inhibitor 61 JAK2 inhibitor 61 Cetrorelix 61 active comparator 61 MYCAMINE 61 novel prodrug 61 Telbivudine 61 Protexia R 61 nucleotide analog 61 CB2 selective receptor agonist 61 beta 1a 61 vicriviroc 61 APF# 61 lintuzumab SGN 61 SILENOR TM 61 latrepirdine 61 aleglitazar 61 MAXY G# 61 BMS# 61 Arimoclomol 61 receptor tyrosine kinase inhibitor 61 CYT# potent vascular disrupting 61 renin inhibitors 61 inecalcitol 61 novel histone deacetylase 61 Entereg R 61 AVN# [001] 61 dose cohorts 61 long acting muscarinic 61 non nucleoside inhibitor 61 CINTREDEKIN BESUDOTOX 61 rBChE 61 preclinical pharmacokinetic 61 thiazolides 61 anticancer activity 61 XOPENEX HFA 61 novel anticancer 61 Ixabepilone 61 Q#IR 61 allosteric modulator 61 5 HT6 receptor 61 subcutaneously administered 61 incyclinide 61 selective androgen receptor modulators 61 direct renin inhibitor 61 confirmatory Phase III 61 renal toxicity 61 DOS# 61 castrate resistant prostate cancer 61 ritonavir boosted 61 AZILECT R 61 Ramoplanin 61 catheter occlusion 61 Lubiprostone 61 PSN# [001] 61 DPP4 inhibitor 61 trodusquemine 61 Welchol 61 seliciclib 61 Tanespimycin 61 immunomodulatory 61 Empatic 61 IDX# 61 Tasimelteon 61 romidepsin 61 Seliciclib 61 alfa 2a 61 Nanobody 61 ataluren 61 DexaSite 61 EVIZON 61 ocrelizumab 61 Harbor BioSciences 61 Aptivus ® 61 OncoVEX 61 Polymer Microspheres 61 generation purine nucleoside 61 isatoribine 61 tafamidis 61 cediranib 61 PRX# 61 Dyloject TM 61 irbesartan 61 PS# DARA 61 COPEGUS 61 APEX PD 61 casopitant 61 pharmacodynamic endpoints 61 vildagliptin 61 QTc prolongation 61 Anturol TM 61 PD LID 61 eosinophilic asthma 61 NP2 Enkephalin 61 Phase III clinical 61 selective kinase inhibitor 61 dosage regimens 61 Diabetic Macular Edema DME 61 rFIXFc 61 Dalbavancin 61 SNT MC# 61 Zemiva ™ 60 nucleoside reverse transcriptase inhibitor 60 DOXIL 60 Lixivaptan 60 mixed dyslipidemia 60 BMS # 60 RAPAFLO 60 RHUCIN 60 Candesartan 60 liposomal doxorubicin 60 CTA# Injection 60 Chrysalin 60 phase IIa 60 EndoTAGTM 1 60 immunomodulation 60 epigenetic therapies 60 pegylated interferons 60 SinuNase 60 hyperphenylalaninemia HPA due 60 Xinlay 60 retapamulin 60 Aztreonam lysine 60 Blinatumomab 60 sPLA2 60 Solazed ™ 60 anti leukemic 60 EndoTAG TM 60 lurasidone 60 Personalized Immunotherapy 60 ALGRX 60 immune modulatory 60 histone deacetylase inhibitor 60 ATHX 60 Fulvestrant 60 XOMA 3AB 60 balsalazide 60 ELADUR 60 Epothilones 60 DG# [001] 60 elagolix 60 BNC# 60 Boceprevir 60 CD# CEA 60 Tarvacin TM 60 MERLIN TIMI 60 HDACi 60 Exherin TM 60 perifosine 60 prokinetic agent 60 Palifosfamide 60 Pharmacokinetic parameters 60 Phase IIb Trial 60 μg dose 60 ambrisentan 60 insulin sensitizer 60 sulodexide 60 vosaroxin 60 Aurora Kinase 60 darapladib 60 Virulizin R 60 Vitaxin 60 CYCLOSET 60 EnzymeRx 60 BLA submission 60 midstage studies 60 potency selectivity 60 tosedostat 60 zalutumumab 60 ZOLINZA 60 clevidipine 60 insulin sensitizing 60 tyrosine kinase inhibitor 60 Atrasentan 60 Vandetanib 60 generation antisense 60 HCV RESPOND 2 60 sitaxsentan 60 ALV# 60 IMPDH inhibitor 60 MOZOBIL 60 IL# PE#QQR 60 Zalbin 60 ISTODAX 60 Annamycin 60 omacetaxine mepesuccinate 60 visilizumab 60 liprotamase 60 dasatinib 60 Ceflatonin 60 ulimorelin 60 cangrelor 60 D aspartate NMDA receptor 60 Thiovir 60 elvucitabine 60 ATL# [002] 60 selective inhibition 60 APTIVUS r 60 vorinostat 60 CCR5 antagonist 60 Pivotal Phase 60 FDA Approvable Letter 60 Angiocept 60 viral kinetic 60 sodium glucose transporter 60 XL# [003] 60 TRISENOX ® 60 Preclinical studies 60 inhaled formulation 60 Telatinib 60 Phase IIb 60 tivozanib 60 FBPase 60 Zenvia ™ 60 AVE# 60 oxymorphone ER 60 Zemiva TM 60 Aurora kinase inhibitor 60 RSD# oral 60 RhuDex 60 sodium thiosulfate STS 60 VEGF Trap 60 edoxaban 60 Metastatic Melanoma 60 Nexavar ® 60 Elocalcitol 60 Initiated Phase 60 antiviral activity 60 TRIOLEX HE# APOPTONE HE# 60 dapagliflozin 60 PI3K/mTOR 60 Liprostin 60 relapsed MM 60 MNTX 60 sphingosine kinase 60 multicenter Phase III 60 SERMs 60 CD3 monoclonal antibody 60 TRX1 60 refractory chronic lymphocytic 60 Neurodex 60 Phase #b/#a 60 Leukine ® 60 nab paclitaxel 60 SLx 60 NEUMUNE 60 delta isoform 60 imetelstat 60 relapsed multiple myeloma 60 blinatumomab 60 veltuzumab 60 delafloxacin 60 octreotide implant 60 cinacalcet HCl 60 PREZISTA r 60 JANUVIA 60 generation Hsp# inhibitor 60 TREDAPTIVE 60 pathophysiological effects 60 FASLODEX 60 OMAPRO 60 OMP #M# 60 oral deforolimus 60 bifeprunox 60 Fibrillex 60 non nucleoside HCV 60 candesartan cilexetil 60 Interferon alpha 60 pharmacodynamic profile 60 trial evaluating PRX# 60 OHR/AVR# 60 dexpramipexole 60 ORMD 60 bardoxolone 60 decitabine 60 secondary efficacy endpoints 60 Phase IIa 60 muraglitazar 60 Solulin 60 glucagon receptor 60 MGCD# [002] 60 docetaxel chemotherapy 60 antitumor activity 60 investigational hepatitis C 60 AKT inhibitor 60 Phase 2a Clinical Trial 60 imatinib Gleevec ® 60 faropenem 60 lenalidomide Revlimid R 60 Phase 1a 60 MTP inhibitor 60 kinase inhibitor 60 budesonide MMX 60 Phase 2b Clinical Trial 60 febuxostat 60 ARIKACE ™ 60 Ereska 60 acetonide FA 60 Numax 60 ON #.Na 60 pharmacodynamic profiles 60 desvenlafaxine succinate 60 synthetic retinoid 60 GEM OS2 60 MAXY alpha 60 azacitidine 60 CCR2 60 SPRYCEL ® 60 Diabetic Macular Edema 60 Fludara 60 tolvaptan 60 Neuradiab 60 Proxinium TM 60 Proellex TM 60 PEG IFN 60 pharmacokinetic interactions 60 Cethromycin 60 Onbrez Breezhaler 60 INGN 60 Ceflatonin R 60 ZYBRESTAT fosbretabulin 60 oral nucleoside analogue 60 Bavituximab 60 hematological tumors 60 AERx iDMS 60 oral JAK1 60 samarium Sm 60 thorough QT 60 NB S# 60 oral proteasome inhibitor 60 Luteinizing Hormone Releasing Hormone 60 ADX# 60 hematologic malignancies 60 angiogenesis inhibitor 60 farletuzumab 60 cetuximab Erbitux ® 60 statistically significant efficacy 60 humanized anti 60 ESBA# 60 5 HT2A inverse 60 alpha 2a 60 Tesetaxel 60 Bendavia 60 iniparib 60 NOX E# 60 PROSTASCINT R 60 peginesatide 60 RIGScan CR 60 zonisamide SR 60 Hycamtin ® 60 investigational compounds 60 nucleoside analogues 60 FLT3 60 Cloretazine ® 60 HZT 60 talabostat 60 Trofex TM 60 PREOS 60 registrational 60 alkylating agent 60 Pharmacokinetic studies 60 IMC A# 60 metastatic castration resistant 60 IND submission 60 canagliflozin